Heartflow, Inc. (NASDAQ:HTFL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Heartflow, Inc. (NASDAQ:HTFL) have been assigned an average rating of “Moderate Buy” from the eight analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $38.50.

A number of research firms have weighed in on HTFL. JPMorgan Chase & Co. upped their target price on Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Wells Fargo & Company assumed coverage on shares of Heartflow in a report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 target price on the stock. Stifel Nicolaus lifted their price target on shares of Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Canaccord Genuity Group boosted their price objective on shares of Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th.

Insiders Place Their Bets

In other news, CEO John C.M. Farquhar sold 22,562 shares of the stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $27.46, for a total value of $619,552.52. Following the sale, the chief executive officer directly owned 591,656 shares of the company’s stock, valued at approximately $16,246,873.76. This represents a 3.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Julie A. Cullivan sold 8,000 shares of Heartflow stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $27.32, for a total value of $218,560.00. Following the completion of the transaction, the director directly owned 36,413 shares of the company’s stock, valued at approximately $994,803.16. This represents a 18.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 2,095,715 shares of company stock valued at $58,533,709.

Institutional Investors Weigh In On Heartflow

A number of institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Heartflow in the fourth quarter worth $27,000. TFC Financial Management Inc. bought a new stake in shares of Heartflow during the 3rd quarter valued at about $40,000. Russell Investments Group Ltd. purchased a new stake in shares of Heartflow during the 4th quarter valued at about $45,000. Legal & General Group Plc bought a new position in shares of Heartflow in the 3rd quarter worth approximately $59,000. Finally, Strs Ohio purchased a new position in shares of Heartflow in the fourth quarter worth approximately $99,000.

Heartflow Stock Down 11.7%

NASDAQ:HTFL opened at $22.16 on Tuesday. The company has a market cap of $1.89 billion and a price-to-earnings ratio of -12.24. Heartflow has a 52 week low of $20.13 and a 52 week high of $41.22. The firm’s fifty day moving average price is $29.47.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.